MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis

By sjmartinez • November 10, 2023

Charles-Schoeman C, Choy E, McInnes IB, Mysler E, Nash P, Yamaoka K, Lippe R, Khan N, Shmagel AK, Palac H, Suboticki J, Curtis JR. MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. RMD Open. 2023 Nov;9(4):e003392. doi: 10.1136/rmdopen-2023-003392. PMID: 37945286.

Tags: Ankylosing, Antirheumatic Agents, Arthritis, Psoriatic, Publications, Rheumatoid, Rheumatology, Spondylitis

Related Posts

Outbreak of New Delhi metallo-β-lactamase carbapenemase-producing Pseudomonas aeruginosa infections in a Southern California hospital

Garrigues JM, Gray HK, Ison RP, Uslan DZ, Lima A, Gonzalez-Ferrer S, Trejo M, Zhuo R, Matysiak Match CJ, Ulloa ER, Bhaurla S, Lewis V,[...]

Exploring the limit of image resolution for human expert classification of vascular ultrasound images in giant cell arteritis and healthy subjects: the GCA-US-AI project

Bauer CJ, Chrysidis S, Dejaco C, Koster MJ, Kohler MJ, Monti S, Schmidt WA, Mukhtyar CB, Karakostas P, Milchert M, Ponte C, Duftner C, de[...]

Asia Pacific Gastroesophageal Cancer Congress (APGCC) 2024 consensus statement on stage 2 and 3 locally advanced gastric and Siewert 3 junctional adenocarcinoma

Masuda Y, Fong KL, Yeo D, Yeo C, Chue KM, Araba SB, Lim CW, Yeung B, Lee J, Lin J, Chia C, Ng M, Ng[...]